Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
McKesson
Express Scripts
Colorcon
AstraZeneca

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

CAM-METRAZINE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Cam-metrazine, and when can generic versions of Cam-metrazine launch?

Cam-metrazine is a drug marketed by Abc Holding, Camall, and Chartwell Rx. and is included in six NDAs.

The generic ingredient in CAM-METRAZINE is phendimetrazine tartrate. There are five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.

US ANDA Litigation and Generic Entry Outlook for Cam-metrazine

A generic version of CAM-METRAZINE was launched as phendimetrazine tartrate by VIRTUS PHARMS on December 14th, 2019.

Summary for CAM-METRAZINE
Drug patent expirations by year for CAM-METRAZINE
Synonyms for CAM-METRAZINE
(2R,3R)-2,3-bis(oxidanyl)butanedioic acid; (2S,3S)-3,4-dimethyl-2-phenyl-morpholine
(2R,3R)-2,3-dihydroxybutanedioic acid; (2S,3S)-3,4-dimethyl-2-phenylmorpholine
(2S,3S)-3,4-Dimethyl-2-phenylmorpholine L-(+)-tartrate (1:1)
21102-82-9
2233-26-3
238P764
50-58-8
6985IP0T80
A828189
AC1L3R57
AC1Q5R36
Adipost
ALPHAZINE
Bontril (TN)
BONTRIL PDM
D-3,4-Dimethyl-2-phenyl-morpholine tartrate
D02080
DI-METREX
DTXSID70198165
EINECS 200-051-0
K631
LS-92795
MELFIAT
MELFIAT-105
Metra
Morpholine, 3,4-dimethyl-2-phenyl-, (+)-, tartrate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, (+)-, tartrate (1:1) (8CI)
Morpholine, 3,4-dimethyl-2-phenyl-, (2S-trans)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, (2S,3S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, tartrate, D-
PHENAZINE-35
Phendimetrazine hydrogen tartrate
Phendimetrazine tartrate
Phendimetrazine tartrate (USP)
Phendimetrazine tartrate [USAN]
Phendimetrazine tartrate [USP]
phendimetrazine tartrate, (2S-trans(R-(R*,R*)))-isomer
Prelu 2
Prelu-2
SCHEMBL160375
Sodium alginate, viscosity ~100mp.s
SPRX
SPRX-105
SPRX-3
Statobex
STATOBEX-G
UNII-6985IP0T80
X-TROZINE L.A
X-trozine L.A.

US Patents and Regulatory Information for CAM-METRAZINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abc Holding CAM-METRAZINE phendimetrazine tartrate TABLET;ORAL 085511-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Chartwell Rx CAM-METRAZINE phendimetrazine tartrate TABLET;ORAL 085318-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Camall CAM-METRAZINE phendimetrazine tartrate TABLET;ORAL 085756-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Chartwell Rx CAM-METRAZINE phendimetrazine tartrate TABLET;ORAL 083922-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Boehringer Ingelheim
Colorcon
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.